Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 54,972 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Melanoma
Interventions: Cemiplimab, Lpilimumab, Fianlimab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cleft Lip, Cleft Lip and Palate
Interventions: Lip revision surgery; Procedure
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 3 Months to 21 Years
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Rheumatoid Arthritis
Interventions: P38 Inhibitor (4) 150mg, P38 Inhibitor (4) 25mg, P38 Inhibitor (4) 300mg, P38 Inhibitor (4) 50mg, P38 Inhibitor (4) 75mg, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 48
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 42 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Aliskiren, Irbesartan, Captopril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heart Failure, Diastolic
Interventions: Furosemide, Dopamine; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Tipranavir, Ritonavir; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: Not listed
Timeline: Started 2004
U.S. locations: 115
States / cities: Anniston, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 74 more

Conditions: Hematological Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Hodgkin's Disease
Interventions: Matched Sibling Allogeneic Transplantation; Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hepatitis C, Liver Diseases
Interventions: Patient portal message; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 54 Years to 74 Years
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Age-Related Macular Degeneration, Geographic Atrophy
Interventions: smaller incision, new generation implantable miniature telescope (SING-IMT); Device
Lead sponsor: VisionCare, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 10
States / cities: Loma Linda, California • Long Beach, California • Sarasota, Florida + 7 more

Conditions: Pancreatic Cancer
Interventions: cisplatin, gemcitabine hydrochloride, surgical procedure, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: New York, New York

Conditions: Post Operative Pain, Gynecologic Cancer
Interventions: Liposomal bupivacaine, Bupivacain; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Head and Neck Cancer, Neck Dissection, Postoperative Complications
Interventions: Porcine Extracellular Matrix Nerve Wrap (AxoGuard Nerve Protector™); Device
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Gout
Interventions: MRI and Ultrasound; Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
Interventions: AZD 1775; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 13
States / cities: Fayetteville, Arkansas • San Francisco, California • West Hollywood, California + 10 more

Conditions: Untreated Adult Acute Myeloid Leukemia
Interventions: Cytarabine, Daunorubicin Hydrochloride, Laboratory Biomarker Analysis, Nilotinib, Pharmacological Study; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 69 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Critical Limb Ischemia
Interventions: Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months., Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months; Drug · Other
Lead sponsor: Leonardo Clavijo; Other
Eligibility: 40 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Multiple Sclerosis
Interventions: Fingolimod 1.25 mg, Fingolimod 0.5 mg, Interferon β-1a 30 µg; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 35
States / cities: Cullman, Alabama • Phoenix, Arizona • Oceanside, California + 31 more

Conditions: Hematological Malignancy
Interventions: Body Scan, Rotterdam Symptom Checklist, Practice Logs; Behavioral · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Not listed
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Leukemia, Acute, Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Interventions: Regulatory T-cells, Conventional T-cells, Melphalan, Thiotepa, Fludarabine, Anti-thymocyte globulin, rabbit, CliniMACS CD34 Reagent System; Drug · Device
Lead sponsor: Everett Meyer; Other
Eligibility: Up to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Arthroplasty, Replacement, Knee
Interventions: (Bupivacaine Liposome Injectable Suspension), Standard Preparation; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Orange, California

Conditions: Alcohol Abuse
Interventions: Protandim; Dietary Supplement
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Prostatic Neoplasms, Prostatic Diseases, Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Recurrent
Interventions: 68GA PSMA-HBED-CC; Drug
Lead sponsor: Jeanne Link; Other
Eligibility: 18 Years and older · Male only
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: gemcitabine hydrochloride, alvocidib, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York

Conditions: Chronic Hepatitis B
Interventions: Peginterferon alfa-2a; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma

Assessing the Results of Lip Surgery in Patients With Cleft Lip and Palate

A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy

A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus

Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies

Electronic Record Assimilation and Subsequent Eradication of Hepatitis C

Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD

Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer

Pilot: Intraoperative TAP Block and Post-operative Pain Control for Minimally Invasive Hysterectomy for Endometrial Cancer

Porcine Extracellular Matrix Nerve Wrap in Neck Dissection for Head and Neck Cancer

MRI and Ultrasound Findings in Patients With Gout and Normal Plain Radiographs

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI)

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

Body Scan Activity on Bone Marrow Transplant Patients and Their Caregivers

Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells

Comparing Post-Op Narcotic Usage in Patients Receiving Periarticular Exparel vs. Standard Periarticular Joint Inj

Antioxidant Replacement Therapy in Patients With Alcohol Abuse

Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer

Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid Tumors

Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment